A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-12-01

Summary

This study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with platinum-based chemotherapy in the first-line treatment of patients with advanced BTC.

• Phase: PHASE3

Details

• Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Treatments: Cisplatin; durvalumab; Gemcitabine; Injections